A promising medication
The medication, called balovaptan, has already shown promising results in adults and has been given breakthrough designation by the Food and Drug Administration (FDA). When Nick decided to enroll in late 2017, the trial was enrolling kids ages 8 to 17. It has since opened to those ages 5 to 7.
“This is the first medication specifically targeting social communication skills in kids with autism,” says Kate Pawlowski, research manager for the study. “Treatments usually mediate symptoms, not the core issues of autism.”